Journal article
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial
Abstract
BACKGROUND: Airway neutrophilic inflammation is a pathological feature in some patients with severe asthma. Stimulation of the chemokine receptor CXCR2 mediates neutrophil migration into the airways. We investigated the safety and efficacy of AZD5069, a CXCR2 antagonist, as an add-on therapy in patients with uncontrolled severe asthma.
METHODS: In this multicentre, randomised, double-blind, placebo-controlled, dose-finding trial, we enrolled …
Authors
O'Byrne PM; Metev H; Puu M; Richter K; Keen C; Uddin M; Larsson B; Cullberg M; Nair P
Journal
The Lancet Respiratory Medicine, Vol. 4, No. 10, pp. 797–806
Publisher
Elsevier
Publication Date
October 2016
DOI
10.1016/s2213-2600(16)30227-2
ISSN
2213-2600